Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD900 phase 3 crossover trial for on-demand treatment of hereditary angioedema attacks
NL-OMON51849Phase 3Recruiting
- Sponsor
- KalVista Pharmaceuticals
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Primary endpoint: PGI-C time to beginning of symptom relief. Started Sep 2022; status: recruiting.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON51849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51849.